menu
    • menu

    Find Buprenorphine manufacturers, exporters & distributors on PharmaCompass

    Buprenorphine

    Virtual Booth

    Contact Supplier

    Buprenorphine Header

    Virtual Booth

    Contact Supplier

    Buprenorphine

    Virtual Booth

    Contact Supplier

    Faran-Shini-Buprenorphine

    Virtual Booth

    Contact Supplier

    SCI PHARMTECH Buprenorphine

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    40

    API Suppliers

    API Suppliers

    12

    USDMF

    US DMFs Filed

    13

    CEP/COS

    CEP/COS Certifications

    2

    JDMF

    JDMFs Filed

    4

    EU WC

    EU WC

    0

    KDMF

    KDMF

    14

    NDC API

    NDC API

    0

    VMF

    NDC API

    22

    Listed Suppliers

    Other Suppliers

    14INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    2

    EDQM

    0

    USP

    0

    JP

    22

    Others

    FINISHED DOSAGE FORMULATIONS

    279

    FDF Dossiers

    FDF Dossiers

    39

    FDA Orange Book

    FDA (Orange Book)

    117

    Europe

    Europe

    6

    Canada

    Canada

    63

    Australia

    Australia

    7

    South Africa

    South Africa

    47

    Listed Dossiers

    Listed Dossiers

    12DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    173RELATED EXCIPIENT COMPANIES

    286EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    103

    US Patents

    9

    US Exclusivities

    7

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 15,127

    GLOBAL SALES INFORMATION

    US Medicaid

    102,881,997

    Annual Reports

    NA

    Regulatory FDF Prices

    Listed Dossiers
    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    11

    API

    5

    FDF

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    200

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Temgesic, Probuphine, Buprenex, 52485-79-7, Buprenophine, Buprenorfina
    Molecular Formula
    C29H41NO4
    Molecular Weight
    467.6  g/mol
    InChI Key
    RMRJXGBAOAMLHD-IHFGGWKQSA-N
    FDA UNII
    40D3SCR4GZ
    Buprenorphine
    A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.
    Buprenorphine is a Partial Opioid Agonist. The mechanism of action of buprenorphine is as a Partial Opioid Agonist.
    1 2D Structure

    Buprenorphine

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
    2.1.2 InChI
    InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1
    2.1.3 InChI Key
    RMRJXGBAOAMLHD-IHFGGWKQSA-N
    2.1.4 Canonical SMILES
    CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O
    2.1.5 Isomeric SMILES
    C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O
    2.2 Other Identifiers
    2.2.1 UNII
    40D3SCR4GZ
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 6029 M

    2. 6029-m

    3. 6029m

    4. Buprenex

    5. Buprenorphine Hydrochloride

    6. Buprex

    7. Hydrochloride, Buprenorphine

    8. Prefin

    9. Rx 6029 M

    10. Rx-6029-m

    11. Rx6029m

    12. Subutex

    13. Temgsic

    14. Temgesic

    2.3.2 Depositor-Supplied Synonyms

    1. Temgesic

    2. Probuphine

    3. Buprenex

    4. 52485-79-7

    5. Buprenophine

    6. Buprenorfina

    7. Buprenorphinum

    8. Butrans

    9. Buprenorfina [inn-spanish]

    10. Buprenorphinum [inn-latin]

    11. (-)-buprenorphine

    12. Buprenorphin

    13. Sublocade

    14. Chebi:3216

    15. Dea No. 9064

    16. 40d3scr4gz

    17. Cam2038

    18. 21-cyclopropyl-7alpha-[(s)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine

    19. Rx 6029m

    20. Brixadi

    21. 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((s)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol

    22. 2-(n-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol

    23. Probuphenine

    24. Temgesic (tn)

    25. (1s,2s,6r,14r,15r,16r)-5-(cyclopropylmethyl)-16-[(2s)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol

    26. 2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14r)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol

    27. 6029-m

    28. Buprenorphine (jan/inn)

    29. Chembl560511

    30. Unii-40d3scr4gz

    31. Buvidal

    32. Buprenorphine [inn:ban:jan]

    33. Alks-5461 Component Buprenorphine

    34. Einecs 257-950-6

    35. Bema

    36. [5alpha,7alpha(s)]-

    37. Buprenorphine [mi]

    38. Buprenorphine [inn]

    39. Buprenorphine [jan]

    40. Schembl15821

    41. Buprenorphine [vandf]

    42. (5alpha,6beta,14beta,18r)-17-(cyclopropylmethyl)-18-[(2s)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol

    43. 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((s)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol

    44. 2-(n-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol

    45. 21-(cyclopropyl-7alpha-((s)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine

    46. Buprenorphine [mart.]

    47. Buprenorphine [who-dd]

    48. Gtpl1670

    49. Buprenorphine [ema Epar]

    50. Dtxsid2022705

    51. Buprenorphine [ep Impurity]

    52. Buprenorphine [orange Book]

    53. Sixmo (buprenorphine Hydrochloride)

    54. Rbp-6000

    55. Zinc1319780

    56. Buprenorphine [ep Monograph]

    57. Bdbm50026603

    58. Db00921

    59. [5alpha,7alpha(s)]-17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol

    60. 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine

    61. 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-.alpha.-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-.alpha.-methyl-, (.alpha.s,5.alpha.,7.alpha.)-

    62. C08007

    63. D07132

    64. Q407721

    65. (1s,2r,6s,14r,15r,16r)-3-(cyclopropylmethyl)-16-[(2s)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1^{2,8}.0^{1,6}.0^{6,14}.0^{7,12}]icosa-7(12),8,10-trien-11-ol

    66. (1s,2r,6s,14r,15r,16r)-3-(cyclopropylmethyl)-16-[(2s)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1^{2,8}.0^{1,6}.0^{6,14}.0^{7,12}]icosa-7,9,11-trien-11-ol

    67. (2s)-2-[(5r,6r,7r,14s)-9alpha-cyclopropylmethyl-3-hydroxy-6-methoxy-4,5-epoxy-6,14-ethanomorphinan-7-yl]-3,3-dimethylbutan-2-ol

    68. 6,14-ethenomorphinan-3-ol, 17-(cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-7-[(1s)-1-hydroxy-1,2,2-trimethylpropyl]-6-methoxy-, (5alpha,7alpha)-

    69. 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-,

    70. 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5-alpha,7-alpha-(s))-

    71. 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphas,5alpha,7alpha)- (9ci)

    2.4 Create Date
    2005-06-01
    3 Chemical and Physical Properties
    Molecular Weight 467.6 g/mol
    Molecular Formula C29H41NO4
    XLogP35
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count5
    Exact Mass467.30355879 g/mol
    Monoisotopic Mass467.30355879 g/mol
    Topological Polar Surface Area62.2 Ų
    Heavy Atom Count34
    Formal Charge0
    Complexity869
    Isotope Atom Count0
    Defined Atom Stereocenter Count7
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 4  
    Drug NameBuprenex
    PubMed HealthBuprenorphine (Injection)
    Drug ClassesAnalgesic, Anesthetic Adjunct
    Drug LabelBuprenex (buprenorphine hydrochloride) is a narcotic under the Controlled Substances Act due to its chemical derivation from thebaine. Chemically, it is 17-(cyclopropylmethyl)--(1,1-dimethylethyl)-4, 5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy--met...
    Active IngredientBuprenorphine hydrochloride
    Dosage FormInjectable
    RouteInjection
    Strengtheq 0.3mg base/ml; 0.3mg
    Market StatusPrescription
    CompanyReckitt Benckiser; Norwich-eaton Pharma

    2 of 4  
    Drug NameButrans
    PubMed HealthBuprenorphine (Absorbed through the skin)
    Drug ClassesAnalgesic
    Drug LabelButrans is a transdermal system providing systemic delivery of buprenorphine, a mu opioid partial agonist analgesic, continuously for 7 days. The chemical name of buprenorphine is 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)- -(1,1-dimet...
    Active IngredientBuprenorphine
    Dosage FormFilm, extended release
    RouteTransdermal
    Strength10mcg/hr; 20mcg/hr; 15mcg/hr; 5mcg/hr; 7.5mcg/hr
    Market StatusPrescription
    CompanyPurdue Pharma

    3 of 4  
    Drug NameBuprenex
    PubMed HealthBuprenorphine (Injection)
    Drug ClassesAnalgesic, Anesthetic Adjunct
    Drug LabelBuprenex (buprenorphine hydrochloride) is a narcotic under the Controlled Substances Act due to its chemical derivation from thebaine. Chemically, it is 17-(cyclopropylmethyl)--(1,1-dimethylethyl)-4, 5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy--met...
    Active IngredientBuprenorphine hydrochloride
    Dosage FormInjectable
    RouteInjection
    Strengtheq 0.3mg base/ml; 0.3mg
    Market StatusPrescription
    CompanyReckitt Benckiser; Norwich-eaton Pharma

    4 of 4  
    Drug NameButrans
    PubMed HealthBuprenorphine (Absorbed through the skin)
    Drug ClassesAnalgesic
    Drug LabelButrans is a transdermal system providing systemic delivery of buprenorphine, a mu opioid partial agonist analgesic, continuously for 7 days. The chemical name of buprenorphine is 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)- -(1,1-dimet...
    Active IngredientBuprenorphine
    Dosage FormFilm, extended release
    RouteTransdermal
    Strength10mcg/hr; 20mcg/hr; 15mcg/hr; 5mcg/hr; 7.5mcg/hr
    Market StatusPrescription
    CompanyPurdue Pharma

    4.2 Drug Indication

    Buprenorphine is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Buprenorphine is also used in combination with [naloxone] in a fixed-dose combination product for the treatment of moderate to severe opioid use disorder.

    FDA Label

    Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Buprenorphine interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, buprenorphine exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Buprenorphine depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. **Dependence** Buprenorphine is a partial agonist at the mu-opioid receptor and chronic administration produces physical dependence of the opioid type, characterized by withdrawal signs and symptoms upon abrupt discontinuation or rapid taper. The withdrawal syndrome is typically milder than seen with full agonists and may be delayed in onset. Buprenorphine can be abused in a manner similar to other opioids. This should be considered when prescribing or dispensing buprenorphine in situations when the clinician is concerned about an increased risk of misuse, abuse, or diversion. **Withdrawal** Abrupt discontinuation of treatment is not recommended as it may result in an opioid withdrawal syndrome that may be delayed in onset. Signs and symptoms may include body aches, diarrhea, gooseflesh, loss of appetite, nausea, nervousness or restlessness, anxiety, runny nose, sneezing, tremors or shivering, stomach cramps, tachycardia, trouble with sleeping, unusual increase in sweating, palpitations, unexplained fever, weakness and yawning. **Risk of Respiratory and Central Nervous System (CNS) Depression and Overdose** Buprenorphine has been associated with life-threatening respiratory depression and death. Many, but not all, post-marketing reports regarding coma and death involved misuse by self-injection or were associated with the concomitant use of buprenorphine and benzodiazepines or other CNS depressant, including alcohol. Use buprenorphine and naloxone sublingual tablets with caution in patients with compromised respiratory function (e.g., chronic obstructive pulmonary disease, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression). **Risk of Overdose in Opioid Nave Patients** There have been reported deaths of opioid-nave individuals who received a 2 mg dose of buprenorphine as a sublingual tablet for analgesia. Buprenorphine and naloxone sublingual tablets are not appropriate as an analgesic in opioid-nave patients. **Precipitation of Opioid Withdrawal Signs and Symptoms** If buprenorphine is started in opioid-dependent individuals, it will displace the other opioids and cause a phenomenon known as "precipitated withdrawal" which is characterized by a rapid and intense onset of withdrawal symptoms. Individuals must therefore be in a state of mild to moderate withdrawal before starting therapy with buprenorphine. Because it contains naloxone, buprenorphine and naloxone sublingual tablets are also highly likely to produce marked and intense withdrawal signs and symptoms if misused parenterally by individuals dependent on full opioid agonists such as heroin, morphine, or methadone. **Gastrointestinal Effects** Buprenorphine and other morphine-like opioids have been shown to decrease bowel motility and cause constipation. Buprenorphine may obscure the diagnosis or clinical course of patients with acute abdominal conditions and should be administered with caution to patients with dysfunction of the biliary tract. **Effects on the Endocrine System** Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon. Chronic use of opioids may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date. Patients presenting with symptoms of androgen deficiency should undergo laboratory evaluation. **Adrenal Insufficiency** Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency. **Use in Patients With Impaired Hepatic Function** Buprenorphine/naloxone products are not recommended in patients with severe hepatic impairment and may not be appropriate for patients with moderate hepatic impairment. The doses of buprenorphine and naloxone in this fixed-dose combination product cannot be individually titrated, and hepatic impairment results in a reduced clearance of naloxone to a much greater extent than buprenorphine. Therefore, patients with severe hepatic impairment will be exposed to substantially higher levels of naloxone than patients with normal hepatic function. This may result in an increased risk of precipitated withdrawal at the beginning of treatment (induction) and may interfere with buprenorphines efficacy throughout treatment. In patients with moderate hepatic impairment, the differential reduction of naloxone clearance compared to buprenorphine clearance is not as great as in subjects with severe hepatic impairment. However, buprenorphine/naloxone products are not recommended for initiation of (treatment induction) in patients with moderate hepatic impairment due to the increased risk of precipitated withdrawal. Buprenorphine/naloxone products may be used with caution for maintenance treatment in patients with moderate hepatic impairment who have initiated treatment on a buprenorphine product without naloxone. However, patients should be carefully monitored and consideration given to the possibility of naloxone interfering with buprenorphines efficacy. **Risk of Hepatitis, Hepatic Events** Cases of cytolytic hepatitis and hepatitis with jaundice have been observed in individuals receiving buprenorphine in clinical trials and through post-marketing adverse event reports. The spectrum of abnormalities ranges from transient asymptomatic elevations in hepatic transaminases to case reports of death, hepatic failure, hepatic necrosis, hepatorenal syndrome, and hepatic encephalopathy. In many cases, the presence of pre-existing liver enzyme abnormalities, infection with hepatitis B or hepatitis C virus, concomitant usage of other potentially hepatotoxic drugs, and ongoing injecting drug use may have played a causative or contributory role. In other cases, insufficient data were available to determine the etiology of the abnormality. Withdrawal of buprenorphine has resulted in amelioration of acute hepatitis in some cases; however, in other cases no dose reduction was necessary. The possibility exists that buprenorphine had a causative or contributory role in the development of the hepatic abnormality in some cases. Liver function tests, prior to initiation of treatment is recommended to establish a baseline. Periodic monitoring of liver function during treatment is also recommended. A biological and etiological evaluation is recommended when a hepatic event is suspected. Depending on the case, buprenorphine and naloxone sublingual tablets may need to be carefully discontinued to prevent withdrawal signs and symptoms and a return by the patient to illicit drug use, and strict monitoring of the patient should be initiated. **Orthostatic Hypotension** Like other opioids, buprenorphine and naloxone sublingual tablets may produce orthostatic hypotension in ambulatory patients. **Elevation of Cerebrospinal Fluid Pressure** Buprenorphine, like other opioids, may elevate cerebrospinal fluid pressure and should be used with caution in patients with head injury, intracranial lesions, and other circumstances when cerebrospinal pressure may be increased. Buprenorphine can produce miosis and changes in the level of consciousness that may interfere with patient evaluation. **Elevation of Intracholedochal Pressure** Buprenorphine has been shown to increase intracholedochal pressure, as do other opioids, and thus should be administered with caution to patients with dysfunction of the biliary tract.

    5.2 MeSH Pharmacological Classification

    Analgesics, Opioid

    Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)

    Narcotics

    Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)

    Narcotic Antagonists

    Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    BUPRENORPHINE
    5.3.2 FDA UNII
    40D3SCR4GZ
    5.3.3 Pharmacological Classes
    Partial Opioid Agonists [MoA]; Partial Opioid Agonist [EPC]
    5.4 ATC Code

    N07BC01

    N07BC01

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    N - Nervous system

    N02 - Analgesics

    N02A - Opioids

    N02AE - Oripavine derivatives

    N02AE01 - Buprenorphine

    N - Nervous system

    N07 - Other nervous system drugs

    N07B - Drugs used in addictive disorders

    N07BC - Drugs used in opioid dependence

    N07BC01 - Buprenorphine

    5.5 Absorption, Distribution and Excretion

    Absorption

    Bioavailablity of buprenorphine/naloxone is very high following intravenous or subcutaneous administration, lower by the sublingual or buccal route, and very low when administered by the oral route. It is therefore provided as a sublingual tablet that is absorbed from the oral mucosa directly into systemic circulation. Clinical pharmacokinetic studies found that there was wide inter-patient variability in the sublingual absorption of buprenorphine and naloxone, but within subjects the variability was low. Both Cmax and AUC of buprenorphine increased in a linear fashion with the increase in dose (in the range of 4 to 16 mg), although the increase was not directly dose-proportional. Buprenorphine combination with naloxone (2mg/0.5mg) provided in sublingual tablets demonstrated a Cmax of 0.780 ng/mL with a Tmax of 1.50 hr and AUC of 7.651 ng.hr/mL. Coadministration with naloxone does not effect the pharmacokinetics of buprenorphine.

    Route of Elimination

    Buprenorphine, like morphine and other phenolic opioid analgesics, is metabolized by the liver and its clearance is related to hepatic blood flow. It is primarily eliminated via feces (as free forms of buprenorphine and norbuprenorphine) while 10 - 30% of the dose is excreted in urine (as conjugated forms of buprenorphine and norbuprenorphine). The overall mean elimination half-life of buprenorphine in plasma ranges from 31 to 42 hours, although the levels are very low 10 hours after dosing (majority of AUC of buprenorphine is captured within 10 hours), indicating that the effective half-life may be shorter.

    Volume of Distribution

    Buprenorphine is highly lipophilic, and therefore extensively distributed, with rapid penetration through the blood-brain barrier. The estimated volume of distribution is 188 - 335 L when given intravenously. It is able to cross into the placenta and breast milk.

    Clearance

    Clearance may be higher in children than in adults. Plasma clearance rate, IV administration, anaesthetized patients = 901.2 39.7 mL/min; Plasma clearance rate, IV administration, healthy subjects = 1042 - 1280 mL/min.

    5.6 Metabolism/Metabolites

    Buprenorphine is metabolized to norbuprenorphine via Cytochrome P450 3A4/3A5-mediated N-dealkylation. Buprenorphine and norbuprenorphine both also undergo glucuronidation to the inactive metabolites buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, respectively. While norbuprenorphine has been found to bind to opioid receptors in-vitro, brain concentrations are very low which suggests that it does not contribute to the clinical effects of buprenorphine. [Naloxone] undergoes direct glucuronidation to naloxone-3-glucuronide as well as N-dealkylation, and reduction of the 6-oxo group.

    Buprenorphine has known human metabolites that include Buprenorphine glucuronide and Norbuprenorphine.

    S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560

    5.7 Biological Half-Life

    Buprenorphine demonstrates slow dissociation kinetics (~166 min), which contributes to its long duration of action and allows for once-daily or even every-second-day dosing. In clinical trial studies, the half-life of sublingually administered buprenorphine/naloxone 2mg/0.5mg was found to be 30.75 hours.

    5.8 Mechanism of Action

    Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. It demonstrates a high affinity for the mu-opioid receptor but has lower intrinsic activity compared to other full mu-opioid agonists such as [heroin], [oxycodone], or [methadone]. This means that buprenorphine preferentially binds the opioid receptor and displaces lower affinity opioids without activating the receptor to a comparable degree. Clinically, this results in a slow onset of action and a clinical phenomenon known as the "ceiling effect" where once a certain dose is reached buprenorphine's effects plateau. This effect can be beneficial, however, as dose-related side effects such as respiratory depression, sedation, and intoxication also plateau at around 32mg, resulting in a lower risk of overdose compared to [methadone] and other full agonist opioids. It also means that opioid-dependent patients do not experience sedation or euphoria at the same rate that they might experience with more potent opioids, improving quality of life for patients with severe pain and reducing the reinforcing effects of opioids which can lead to drug-seeking behaviours. Buprenorphine's high affinity, but low intrinsic activity for the mu-opioid receptor also means that if it is started in opioid-dependent individuals, it will displace the other opioids without creating an equal opioid effect and cause a phenomenon known as "precipitated withdrawal" which is characterized by a rapid and intense onset of withdrawal symptoms (i.e. anxiety, restlessness, gastrointestinal distress, diaphoresis, intense drug cravings, and tachycardia). Individuals must therefore be in a state of mild to moderate withdrawal before starting therapy with buprenorphine. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose combination product along with [naloxone], a non-selective competitive opioid receptor antagonist. Combination of an opioid agonist with an opioid antagonist may seem counterintuitive, however this combination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist effects of buprenorphine if injected intravenously.

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"BUPRENORPHINE HYDROCHLORIDE","year":"2021","qtr":"Q1","strtotime":1610044200,"product":"BUPRENORPHINE HYDROCHLORIDE EP [EXP.PERM","address":"206, ERIC HOUSE, 16TH ROAD,CHEMBUR,","city":"MUMBAI, MAHARASHTRA.","supplier":"PIONEER AGRO EXTRACTS","supplierCountry":"INDIA","foreign_port":"SYDNEY","customer":"T.A.P.LTD.","customerCountry":"AUSTRALIA","quantity":"0.02","actualQuantity":"18","unit":"GMS","unitRateFc":"60","totalValueFC":"1052.8","currency":"USD","unitRateINR":4277.7777777777774,"date":"08-Jan-2021","totalValueINR":"77000","totalValueInUsd":"1052.8","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"7761916","productDescription":"API","marketType":"REGULATED MARKET","country":"AUSTRALIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"206, ERIC HOUSE, 16TH ROAD,CHEMBUR,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"BUPRENORPHINE HYDROCHLORIDE","year":"2021","qtr":"Q1","strtotime":1610649000,"product":"BUPRENORPHINE HYDROCHLORIDE EP [EXP.PERM IT NO.P-EXP-15312\/2020 DT.03.12.2020 IMP .PERMIT.NO.DCS-20-IMP-1762 DT.15.10.2020","address":"206, ERIC HOUSE, 16TH ROAD,CHEMBUR,","city":"MUMBAI, MAHARASHTRA.","supplier":"PIONEER AGRO EXTRACTS","supplierCountry":"INDIA","foreign_port":"SYDNEY","customer":"T.A.P.LTD.","customerCountry":"AUSTRALIA","quantity":"0.02","actualQuantity":"18","unit":"GMS","unitRateFc":"51.4","totalValueFC":"937.4","currency":"USD","unitRateINR":3808.9833333333331,"date":"15-Jan-2021","totalValueINR":"68561.7","totalValueInUsd":"937.4","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"7919745","productDescription":"API","marketType":"REGULATED MARKET","country":"AUSTRALIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"206, ERIC HOUSE, 16TH ROAD,CHEMBUR,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"BUPRENORPHINE HYDROCHLORIDE","year":"2021","qtr":"Q1","strtotime":1615401000,"product":"BUPRENORPHINE HYDROCHLORIDE EP [EXPORT P ERMIT NO.P-EXP-10775\/2021 DT.23.02.2021 IMPORT PERMIT NO.039 DT.20.12.2020]","address":"206, ERIC HOUSE, 16TH ROAD,CHEMBUR,","city":"MUMBAI, MAHARASHTRA.","supplier":"PIONEER AGRO EXTRACTS","supplierCountry":"INDIA","foreign_port":"ALGIERS","customer":"L.L.F.R.","customerCountry":"ALGERIA","quantity":"0.50","actualQuantity":"500","unit":"GMS","unitRateFc":"31.5","totalValueFC":"15598.6","currency":"USD","unitRateINR":2271.1999999999998,"date":"11-Mar-2021","totalValueINR":"1135600","totalValueInUsd":"15598.6","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"9271845","productDescription":"API","marketType":"","country":"ALGERIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"206, ERIC HOUSE, 16TH ROAD,CHEMBUR,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1623090600,"product":"PHARMACEUTICAL ALLOPATHIC RAW MATERIAL O F PHARMACEUTCAL GRADE:BUPRENORPHINE HCL BP(GROSS WT.1.51995 KG NET WT.0.01995 KG","address":"66\/70;PRINCESS STREETROOM NO.18, RANVEER BUILDING","city":"MUMBAI, ,MAHARASHTRA","supplier":"MICRO ORGO CHEM","supplierCountry":"INDIA","foreign_port":"LAHORE","customer":"JS BANK LTD","customerCountry":"PAKISTAN","quantity":"0.02","actualQuantity":"19.95","unit":"GMS","unitRateFc":"158.3","totalValueFC":"3093.7","currency":"USD","unitRateINR":11404.959398496241,"date":"08-Jun-2021","totalValueINR":"227528.94","totalValueInUsd":"3093.7","indian_port":"BOMBAY AIR","hs_no":"29391100","bill_no":"2282642","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"66\/70;PRINCESS STREETROOM NO.18, RANVEER BUILDING, MUMBAI, ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1623177000,"product":"BUPRENORPHINE HYDROCHLORIDE USP - BULK D RUG *EXP. PERMIT NO: P-EXP-12155\/2021 DT :24.05.2021 IMP PERMIT NO.DHFS110PI01478","address":"ACME PLAZA, ANDHERI KURLA ROAD,ANDHERI EAST","city":"MUMBAI, MAHARASHTRA.","supplier":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"FOREFRONT ENTERPRISE CO. ","customerCountry":"TAIWAN","quantity":"1.18","actualQuantity":"1.175","unit":"KGS","unitRateFc":"19748.6","totalValueFC":"22732.8","currency":"USD","unitRateINR":1422889.0553191488,"date":"09-Jun-2021","totalValueINR":"1671894.64","totalValueInUsd":"22732.8","indian_port":"BOMBAY AIR","hs_no":"29391100","bill_no":"2310757","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ACME PLAZA, ANDHERI KURLA ROAD,ANDHERI EAST, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1624213800,"product":"BUPRENORPHINE PHYDROCHLORIDE USP[EXPORT. PERMIT.NO.P-EXP-11795\/2021 DT.30.04.2021 IMPORT.PERMIT.NO.0402001 DT.02.04.2021]","address":"206, ERIC HOUSE, 16TH ROAD,CHEMBUR,","city":"MUMBAI, MAHARASHTRA.","supplier":"PIONEER AGRO EXTRACTS","supplierCountry":"INDIA","foreign_port":"TOKYO","customer":"TO ORDER","customerCountry":"JAPAN","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"149.7","totalValueFC":"14662.2","currency":"USD","unitRateINR":10783.43,"date":"21-Jun-2021","totalValueINR":"1078343","totalValueInUsd":"14662.2","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"2572955","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"206, ERIC HOUSE, 16TH ROAD,CHEMBUR,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1624905000,"product":"BUPRENORPHINE HYDROCHLORIDE EP [EXP PERM IT NO.P-EXP-12440\/2021 DT.09.06.2021 IMP PERMIT NO.I0869-21 DATED 29.04.2021]","address":"206, ERIC HOUSE, 16TH ROAD,CHEMBUR,","city":"MUMBAI, MAHARASHTRA.","supplier":"PIONEER AGRO EXTRACTS","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"A. C. INC.","customerCountry":"CANADA","quantity":"0.20","actualQuantity":"200","unit":"GMS","unitRateFc":"49","totalValueFC":"9607.2","currency":"USD","unitRateINR":3532.8449999999998,"date":"29-Jun-2021","totalValueINR":"706569","totalValueInUsd":"9607.2","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"2756719","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"206, ERIC HOUSE, 16TH ROAD,CHEMBUR,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1626805800,"product":"PHARMACEUTICAL ALLOPATHIC RAW MATERIAL O F PHARMACEUTICAL GRADE: BUPRENORPHINE HY DROCHLORIDE BP","address":"206, ERIC HOUSE, 16TH ROAD,CHEMBUR,","city":"MUMBAI, MAHARASHTRA.","supplier":"PIONEER AGRO EXTRACTS","supplierCountry":"INDIA","foreign_port":"LAHORE","customer":"BANK AL HABIB ","customerCountry":"PAKISTAN","quantity":"0.11","actualQuantity":"110.15","unit":"GMS","unitRateFc":"31.2","totalValueFC":"3325.2","currency":"USD","unitRateINR":2249.8044484793463,"date":"21-Jul-2021","totalValueINR":"247815.96","totalValueInUsd":"3325.2","indian_port":"BOMBAY AIR","hs_no":"29242990","bill_no":"3276159","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"206, ERIC HOUSE, 16TH ROAD,CHEMBUR,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1634668200,"product":"BUPRENORPHINE HYDROCHLORIDE USP (BASIC S","address":"PLOT NO.58-D,GOVT. INDL.ESTATE,CHARKOP,KANDIVALI,","city":"MUMBAI ,MAHARASHTRA","supplier":"RUSAN PHARMA","supplierCountry":"INDIA","foreign_port":"TEHRAN","customer":"DAROU DARMAN PARS.,","customerCountry":"IRAN","quantity":"70.00","actualQuantity":"70","unit":"KGS","unitRateFc":"13000","totalValueFC":"877136.1","currency":"EUR","unitRateINR":938685.71428571432,"date":"20-Oct-2021","totalValueINR":"65708000","totalValueInUsd":"877136.1","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"5403987","productDescription":"API","marketType":"","country":"IRAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT NO.58-D,GOVT. INDL.ESTATE,CHARKOP,KANDIVALI,, MUMBAI ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1635273000,"product":"BUPRENORPHINE HYDROCHLORIDE EP (BASIC SU","address":"PLOT NO.58-D,GOVT. INDL.ESTATE,CHARKOP,KANDIVALI,","city":"MUMBAI ,MAHARASHTRA","supplier":"RUSAN PHARMA","supplierCountry":"INDIA","foreign_port":"SHENZHEN","customer":"SHENZHEN SCIENCARE MEDICAL INDUSTRI","customerCountry":"CHINA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"32000","totalValueFC":"31610.4","currency":"USD","unitRateINR":2368000,"date":"27-Oct-2021","totalValueINR":"2368000","totalValueInUsd":"31610.4","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"5614891","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT NO.58-D,GOVT. INDL.ESTATE,CHARKOP,KANDIVALI,, MUMBAI ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1635791400,"product":"BUPRENORPHINE HYDROCHLORIDE EP [EXP.PMT.","address":"206, ERIC HOUSE, 16TH ROAD,CHEMBUR,","city":"MUMBAI, MAHARASHTRA.","supplier":"SANVIN LABORATORIES PVT LTD","supplierCountry":"INDIA","foreign_port":"TOKYO","customer":"F. & C. LTD.","customerCountry":"JAPAN","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"192.9","totalValueFC":"19134.9","currency":"USD","unitRateINR":14250,"date":"02-Nov-2021","totalValueINR":"1425000","totalValueInUsd":"19134.9","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"5782977","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"206, ERIC HOUSE, 16TH ROAD,CHEMBUR,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1647887400,"product":"BUPRENORPHINE HYDROCHLORIDE (IN-HOUSE) (","address":"PLOT NO 58- D GOVT. INDUSTRIAL ESTA CHARKOP KANDIVALI","city":"MUMBAI","supplier":"RUSAN PHARMA","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"FSUE MOSCOW ENDOCRINE ","customerCountry":"RUSSIA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"210000","totalValueFC":"61978.9","currency":"USD","unitRateINR":15746666.666666668,"date":"22-Mar-2022","totalValueINR":"4724000","totalValueInUsd":"61978.9","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"9102112","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT NO 58- D GOVT. INDUSTRIAL ESTA CHARKOP KANDIVALI, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1649701800,"product":"BUPRENORPHINE HYDROCHLORIDE EP [EXPORT P","address":"206, ERIC HOUSE, 16TH ROAD, CHEMBUR,","city":"MUMBAI, MAHARASHTRA.","supplier":"SANVIN LABORATORIES PVT LTD","supplierCountry":"INDIA","foreign_port":"TOKYO","customer":"F & C. LTD.","customerCountry":"JAPAN","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"150000","totalValueFC":"14884.2","currency":"USD","unitRateINR":11230000,"date":"12-Apr-2022","totalValueINR":"1123000","totalValueInUsd":"14884.2","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"9638711","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"206, ERIC HOUSE, 16TH ROAD, CHEMBUR,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1656527400,"product":"BUPRENORPHINE HYDROCHLORIDE EP [EXP PERM","address":"206, ERIC HOUSE, 16TH ROAD, CHEMBUR,","city":"MUMBAI, MAHARASHTRA.","supplier":"PIONEER AGRO INDUSTRIES SANVIN LABORATORIES PRIVAT","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"A.C.INC.","customerCountry":"CANADA","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"50000","totalValueFC":"9869.9","currency":"USD","unitRateINR":3850000,"date":"30-Jun-2022","totalValueINR":"770000","totalValueInUsd":"9869.9","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"2507939","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"206, ERIC HOUSE, 16TH ROAD, CHEMBUR,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1664217000,"product":"BUPRENORPHINE EP (BASE CONTENT\/SUBSTANCE","address":"PLOT NO 58- D GOVT. INDUSTRIAL ESTA CHARKOP KANDIVALI","city":"MUMBAI","supplier":"RUSAN PHARMA","supplierCountry":"INDIA","foreign_port":"MADRID","customer":"LABORATORIOS FARMACEUTICOS ROVI","customerCountry":"SPAIN","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"26500","totalValueFC":"51958.4","currency":"USD","unitRateINR":2082000,"date":"27-Sep-2022","totalValueINR":"4164000","totalValueInUsd":"51958.4","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"4471235","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT NO 58- D GOVT. INDUSTRIAL ESTA CHARKOP KANDIVALI, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1664389800,"product":"BUPRENORPHINE HYDROCHLORIDE EP(BASIC SUB","address":"PLOT NO 58- D GOVT. INDUSTRIAL ESTA CHARKOP KANDIVALI","city":"MUMBAI","supplier":"RUSAN PHARMA","supplierCountry":"INDIA","foreign_port":"LISBON","customer":"I GEN LDA","customerCountry":"PORTUGAL","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"10000","totalValueFC":"58247.3","currency":"EUR","unitRateINR":778000,"date":"29-Sep-2022","totalValueINR":"4668000","totalValueInUsd":"58247.3","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"4505851","productDescription":"API","marketType":"REGULATED MARKET","country":"PORTUGAL","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT NO 58- D GOVT. INDUSTRIAL ESTA CHARKOP KANDIVALI, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677695400,"product":"BUPRENORPHINE HYDROCHLORIDE EP [EXPORT P","address":"206, ERIC HOUSE, 16TH ROAD, CHEMBUR,","city":"MUMBAI, MAHARASHTRA.","supplier":"PIONEER AGRO INDUSTRIES SANVIN LABORATORIES PRIVAT","supplierCountry":"INDIA","foreign_port":"ALGIERS","customer":"L. L. F. R. SPA","customerCountry":"ALGERIA","quantity":"1.00","actualQuantity":"1000","unit":"GMS","unitRateFc":"32.7","totalValueFC":"32413.2","currency":"USD","unitRateINR":2666,"date":"02-Mar-2023","totalValueINR":"2666000","totalValueInUsd":"32413.2","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"8180997","productDescription":"API","marketType":"","country":"ALGERIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"206, ERIC HOUSE, 16TH ROAD, CHEMBUR,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1683657000,"product":"HS CODE 29391100 ITEM CODE 2026844 HARMLESS PHARMACEUTICAL BULK DRUG BUPRENORPHINE HYDROCHLORIDE USP","address":"SPARC TANDALJA","city":"VADODARA","supplier":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","supplierCountry":"INDIA","foreign_port":"SHANGHAI","customer":"YICHANG HUMANWELL PHARMACEUTICAL","customerCountry":"CHINA","quantity":"25.20","actualQuantity":"25.2","unit":"KGS","unitRateFc":"22333","totalValueFC":"416811.4","currency":"USD","unitRateINR":1360992.0634920634,"date":"10-May-2023","totalValueINR":"34297000","totalValueInUsd":"416811.4","indian_port":"BOMBAY AIR","hs_no":"29391100","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"SPARC TANDALJA, VADODARA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703269800,"product":"PHARMACEUTICAL RAW MATERIAL : BUPRENORPHINE HCL BP","address":"66\/70;PRINCESS STREET","city":"MUMBAI, ,MAHARASHTRA","supplier":"MICRO ORGO CHEM","supplierCountry":"INDIA","foreign_port":"ISLAMABAD - ISLAMABA","customer":"BANK AL HABIB ","customerCountry":"PAKISTAN","quantity":"0.16","actualQuantity":"157.5","unit":"GMS","unitRateFc":"27","totalValueFC":"4120.5","currency":"USD","unitRateINR":2177.7777777777778,"date":"23-Dec-2023","totalValueINR":"343000","totalValueInUsd":"4120.5","indian_port":"Bombay Air","hs_no":"29391100","bill_no":"6262862","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"66\/70;PRINCESS STREET, MUMBAI, ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703269800,"product":"PHARMACEUTICAL RAW MATERIAL : BUPRENORPHINE HCL BP","address":"66\/70;PRINCESS STREET","city":"MUMBAI, ,MAHARASHTRA","supplier":"MICRO ORGO CHEM","supplierCountry":"INDIA","foreign_port":"LAHORE","customer":"UNITED BANK LIMITED","customerCountry":"PAKISTAN","quantity":"0.29","actualQuantity":"291.79","unit":"GMS","unitRateFc":"31","totalValueFC":"8889.6","currency":"USD","unitRateINR":2536.0704616333664,"date":"23-Dec-2023","totalValueINR":"740000","totalValueInUsd":"8889.6","indian_port":"Bombay Air","hs_no":"29391100","bill_no":"6265257","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"66\/70;PRINCESS STREET, MUMBAI, ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1710700200,"product":"PHARMACEUTICAL RAW MATERIAL ACTIVE PHARMACEUTICAL INGREDIENT BUPRENORPHINE HYDROCHLORIDE EP","address":"206, ERIC HOUSE, 16TH ROAD,","city":"MUMBAI, MAHARASHTRA.","supplier":"PIONEER AGRO INDUSTRIES SANVIN LABORATORIES PRIVAT","supplierCountry":"INDIA","foreign_port":"TOKYO","customer":"F. & CO. LTD","customerCountry":"JAPAN","quantity":"0.54","actualQuantity":"0.54","unit":"KGS","unitRateFc":"74074.1","totalValueFC":"39429","currency":"USD","unitRateINR":6062988.8888888881,"date":"18-Mar-2024","totalValueINR":"3274014","totalValueInUsd":"39429","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"8421901","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"206, ERIC HOUSE, 16TH ROAD,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1727289000,"product":"BUPRENORPHINE HYDROCHLORIDE BASIC SUBSTANCE \/CONTENT BUPRENORPHINE 6.496 KGS *FILE NO: POR\/EXP\/JUL 2024\/000021","address":"PLOT NO.58-D,GOVT. INDL.ESTATE,","city":"MUMBAI ,MAHARASHTRA","supplier":"RUSAN PHARMA","supplierCountry":"INDIA","foreign_port":"LISBON","customer":"I GEN LDA","customerCountry":"PORTUGAL","quantity":"7.00","actualQuantity":"7","unit":"KGS","unitRateFc":"9000","totalValueFC":"64880","currency":"EUR","unitRateINR":776718.14285714284,"date":"26-Sep-2024","totalValueINR":"5437027","totalValueInUsd":"64880","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"4366097","productDescription":"API","marketType":"REGULATED MARKET","country":"PORTUGAL","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT NO.58-D,GOVT. INDL.ESTATE,, MUMBAI ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1731004200,"product":"BUPRENORPHINE HYDROCHLORIDE USP (ACT QTY. 0.300 KG)","address":"ACME PLAZA, ANDHERI KURLA ROAD,","city":"MUMBAI, MAHARASHTRA.","supplier":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","supplierCountry":"INDIA","foreign_port":"ATLANTA, HARTSFIELD","customer":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","customerCountry":"UNITED STATES","quantity":"0.30","actualQuantity":"300","unit":"GMS","unitRateFc":"9","totalValueFC":"2389.9","currency":"USD","unitRateINR":672.27376666666669,"date":"08-Nov-2024","totalValueINR":"201682.13","totalValueInUsd":"2389.9","indian_port":"Bombay Air","hs_no":"29391100","bill_no":"5452782","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"ACME PLAZA, ANDHERI KURLA ROAD,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1732732200,"product":"ITEM CODE : 8039038 HSN CODE : 29391100HARMLESS PHARMACEUTICAL BULK DRUG BUPRENORPHINE BASE (STAGE-VI)","address":"ACME PLAZA, ANDHERI KURLA ROAD,","city":"MUMBAI, MAHARASHTRA.","supplier":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","supplierCountry":"INDIA","foreign_port":"ATLANTA, HARTSFIELD","customer":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","customerCountry":"UNITED STATES","quantity":"75.00","actualQuantity":"75","unit":"KGS","unitRateFc":"6200","totalValueFC":"459690.6","currency":"USD","unitRateINR":517232.76173333335,"date":"28-Nov-2024","totalValueINR":"38792457.13","totalValueInUsd":"459690.6","indian_port":"Bombay Air","hs_no":"29391100","bill_no":"5976291","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"ACME PLAZA, ANDHERI KURLA ROAD,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1738002600,"product":"PHARMACEUTICAL RAW MATERIAL ACTIVEPHARMACEUTICAL INGREDIENT BUPRENORPHINE HYDROCHLORIDE EP","address":"206, ERIC HOUSE, 16TH ROAD,","city":"MUMBAI, MAHARASHTRA.","supplier":"PIONEER AGRO INDUSTRIES SANVIN LABORATORIES PRIVAT","supplierCountry":"INDIA","foreign_port":"TOKYO - NARITA","customer":"F. & C. AG","customerCountry":"JAPAN","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"150","totalValueFC":"14810.3","currency":"USD","unitRateINR":12770.799999999999,"date":"28-Jan-2025","totalValueINR":"1277080","totalValueInUsd":"14810.3","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"7655759","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"206, ERIC HOUSE, 16TH ROAD,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1738607400,"product":"PHARMACEUTICAL RAW MATERIAL OF PHARMACEUTICAL GRADE : BUPRENORPHINE HCL BP","address":"66\/70;PRINCESS STREET","city":"MUMBAI, ,MAHARASHTRA","supplier":"MICRO ORGO CHEM","supplierCountry":"INDIA","foreign_port":"LAHORE","customer":"BANK AL HABIB ","customerCountry":"PAKISTAN","quantity":"0.14","actualQuantity":"135.49","unit":"GMS","unitRateFc":"25","totalValueFC":"3228.6","currency":"USD","unitRateINR":2072.2647427854454,"date":"04-Feb-2025","totalValueINR":"280771.15","totalValueInUsd":"3228.6","indian_port":"Bombay Air","hs_no":"29391100","bill_no":"7887490","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"66\/70;PRINCESS STREET, MUMBAI, ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1741026600,"product":"SAP CODE : 8039038 HARMLESS PHARMACEUTICAL BULK DRUG : BUPRENORPHINE BASE (STAGE-VI) (BUPRENORPHINE)","address":"ACME PLAZA, ANDHERI KURLA ROAD,","city":"MUMBAI, MAHARASHTRA.","supplier":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","supplierCountry":"INDIA","foreign_port":"ATLANTA, HARTSFIELD","customer":"M\/S.","customerCountry":"UNITED STATES","quantity":"175.00","actualQuantity":"175","unit":"KGS","unitRateFc":"6200","totalValueFC":"1074953.1","currency":"USD","unitRateINR":532056.21714285715,"date":"04-Mar-2025","totalValueINR":"93109838","totalValueInUsd":"1074953.1","indian_port":"Bombay Air","hs_no":"29391100","bill_no":"8710600","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"ACME PLAZA, ANDHERI KURLA ROAD,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1665685800,"product":"BUPRENORPHINE HCI","address":"MED ONE HOUSE, PLOT NO B-75, RD NO ,Z-33, WAGLE INDUSTRIAL ESTATE,","city":"THANE,MAHARASHTRA","supplier":"VERANOVA","supplierCountry":"UNITED KINGDOM","foreign_port":"NA","customer":"RUBICON RESEARCH","customerCountry":"INDIA","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"12000","totalValueFC":"36072.5","currency":"USD","unitRateINR":"989400","date":"14-Oct-2022","totalValueINR":"2968200","totalValueInUsd":"36072.5","indian_port":"BOMBAY AIR","hs_no":"29391100","bill_no":"2885237","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"MED ONE HOUSE, PLOT NO B-75, RD NO ,Z-33, WAGLE INDUSTRIAL ESTATE,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1707157800,"product":"BUPRENORPHINE HCL USP (BUPRENORPHINE HYDROCHLORIDE) (CBN NOP\/IMP-10024\/2024 DT.15.01.2024)","address":"221, GOREGAON-MULUND LINK ROAD,","city":"BHANDUP WEST, MUMBAI","supplier":"M\/S. MACLARAN SMITH LIMITED","supplierCountry":"UNITED KINGDOM","foreign_port":"EDINBURGH","customer":"RUBICON RESEARCH","customerCountry":"INDIA","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"12000","totalValueFC":"121411.8","currency":"USD","unitRateINR":"1007400","date":"06-Feb-2024","totalValueINR":"10074000","totalValueInUsd":"121411.8","indian_port":"Bombay Air","hs_no":"29391100","bill_no":"9999742","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"EDINBURGH","supplierAddress":"10 WHEATFIELD ROADEDINBURGH EH11 2QAUNITED KINGDOM GB","customerAddress":"221, GOREGAON-MULUND LINK ROAD,"}]
    08-Jan-2021
    04-Mar-2025
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API/FDF Prices: Book a Demo to explore the features and consider upgrading later

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - FILM, EXTENDED RELEASE;TRANSDERMAL -...DOSAGE - FILM, EXTENDED RELEASE;TRANSDERMAL - 10MCG/HR

    USFDA APPLICATION NUMBER - 21306

    read-more

    DOSAGE - FILM, EXTENDED RELEASE;TRANSDERMAL -...DOSAGE - FILM, EXTENDED RELEASE;TRANSDERMAL - 15MCG/HR

    USFDA APPLICATION NUMBER - 21306

    read-more

    DOSAGE - FILM, EXTENDED RELEASE;TRANSDERMAL -...DOSAGE - FILM, EXTENDED RELEASE;TRANSDERMAL - 20MCG/HR

    USFDA APPLICATION NUMBER - 21306

    read-more

    DOSAGE - FILM, EXTENDED RELEASE;TRANSDERMAL -...DOSAGE - FILM, EXTENDED RELEASE;TRANSDERMAL - 5MCG/HR

    USFDA APPLICATION NUMBER - 21306

    read-more

    DOSAGE - FILM, EXTENDED RELEASE;TRANSDERMAL -...DOSAGE - FILM, EXTENDED RELEASE;TRANSDERMAL - 7.5MCG/HR

    USFDA APPLICATION NUMBER - 21306

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Topical

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Looking for 52485-79-7 / Buprenorphine API manufacturers, exporters & distributors?

    Buprenorphine manufacturers, exporters & distributors 1

    93

    PharmaCompass offers a list of Buprenorphine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Buprenorphine manufacturer or Buprenorphine supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Buprenorphine manufacturer or Buprenorphine supplier.

    PharmaCompass also assists you with knowing the Buprenorphine API Price utilized in the formulation of products. Buprenorphine API Price is not always fixed or binding as the Buprenorphine Price is obtained through a variety of data sources. The Buprenorphine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Buprenorphine

    Synonyms

    Temgesic, Probuphine, Buprenex, 52485-79-7, Buprenophine, Buprenorfina

    Cas Number

    52485-79-7

    Unique Ingredient Identifier (UNII)

    40D3SCR4GZ

    About Buprenorphine

    A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.

    Buprenorphine Manufacturers

    A Buprenorphine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Buprenorphine, including repackagers and relabelers. The FDA regulates Buprenorphine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Buprenorphine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Buprenorphine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Buprenorphine Suppliers

    A Buprenorphine supplier is an individual or a company that provides Buprenorphine active pharmaceutical ingredient (API) or Buprenorphine finished formulations upon request. The Buprenorphine suppliers may include Buprenorphine API manufacturers, exporters, distributors and traders.

    click here to find a list of Buprenorphine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Buprenorphine USDMF

    A Buprenorphine DMF (Drug Master File) is a document detailing the whole manufacturing process of Buprenorphine active pharmaceutical ingredient (API) in detail. Different forms of Buprenorphine DMFs exist exist since differing nations have different regulations, such as Buprenorphine USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Buprenorphine DMF submitted to regulatory agencies in the US is known as a USDMF. Buprenorphine USDMF includes data on Buprenorphine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Buprenorphine USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Buprenorphine suppliers with USDMF on PharmaCompass.

    Buprenorphine JDMF

    The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

    The Buprenorphine Drug Master File in Japan (Buprenorphine JDMF) empowers Buprenorphine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

    PMDA reviews the Buprenorphine JDMF during the approval evaluation for pharmaceutical products. At the time of Buprenorphine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

    click here to find a list of Buprenorphine suppliers with JDMF on PharmaCompass.

    Buprenorphine CEP

    A Buprenorphine CEP of the European Pharmacopoeia monograph is often referred to as a Buprenorphine Certificate of Suitability (COS). The purpose of a Buprenorphine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Buprenorphine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Buprenorphine to their clients by showing that a Buprenorphine CEP has been issued for it. The manufacturer submits a Buprenorphine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Buprenorphine CEP holder for the record. Additionally, the data presented in the Buprenorphine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Buprenorphine DMF.

    A Buprenorphine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Buprenorphine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

    click here to find a list of Buprenorphine suppliers with CEP (COS) on PharmaCompass.

    Buprenorphine WC

    A Buprenorphine written confirmation (Buprenorphine WC) is an official document issued by a regulatory agency to a Buprenorphine manufacturer, verifying that the manufacturing facility of a Buprenorphine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Buprenorphine APIs or Buprenorphine finished pharmaceutical products to another nation, regulatory agencies frequently require a Buprenorphine WC (written confirmation) as part of the regulatory process.

    click here to find a list of Buprenorphine suppliers with Written Confirmation (WC) on PharmaCompass.

    Buprenorphine NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Buprenorphine as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Buprenorphine API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Buprenorphine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Buprenorphine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Buprenorphine NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Buprenorphine suppliers with NDC on PharmaCompass.

    Buprenorphine GMP

    Buprenorphine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Buprenorphine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Buprenorphine GMP manufacturer or Buprenorphine GMP API supplier for your needs.

    Buprenorphine CoA

    A Buprenorphine CoA (Certificate of Analysis) is a formal document that attests to Buprenorphine's compliance with Buprenorphine specifications and serves as a tool for batch-level quality control.

    Buprenorphine CoA mostly includes findings from lab analyses of a specific batch. For each Buprenorphine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Buprenorphine may be tested according to a variety of international standards, such as European Pharmacopoeia (Buprenorphine EP), Buprenorphine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Buprenorphine USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search